Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-0.96%
$14.09
100% positive prob.
5-Day Prediction
+3.55%
$14.73
100% positive prob.
20-Day Prediction
-14.04%
$12.23
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | -0.96% | +3.55% | -14.04% | 100.0% | Pending |
| Q2 2026 | BUY | -0.95% | +3.52% | -13.93% | 98.5% | Pending |
| Q4 2025 | SELL | -13.54% | -19.74% | -24.99% | 100.0% | Pending |
| Q3 2025 | SELL | -14.74% | -21.41% | -24.70% | 100.0% | -13.09% |
SEC 8-K filings with transcript text
Nov 16, 2026 · 100% conf.
1D
-0.96%
$14.09
Act: -80.11%
5D
+3.55%
$14.73
20D
-14.04%
$12.23
2 cue-ex99_1.htm
Exhibit 99.1
Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
• CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and food allergy
• CUE-401 enters clinical development with initiation of first-in-human dosing, achieving key 2026 milestone
• Operating results reflect expenditures related to initiation of clinical development program expenses and non-cash charges
BOSTON, November 16, 2026 – Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported third quarter 2026 financial results as well as recent business highlights.
“We are seeing exciting momentum across our portfolio,” said Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma. “We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy. The additional clinical and pharmacological findings shared today from our Phase 2 CSU study reinforce CUE-221’s differentiated profile in CSU and provide a strong foundation to advance our food allergy program. In addition, commencement of dosing in our CUE-401 Phase 1 trial marks a significant milestone for Cue Biopharma as our first autoimmune therapeutic candidate enters the clinic.”
“Our goal is to move beyond partial protection toward more complete, sustained protection for patients, including those with high baseline IgE who remain underserved by current therapies. In parallel, we are advancing half-life extension efforts for CUE-221, aimed at further enhancing patient convenience,” said Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma.
“CUE-401 is a potentially first-in-class dual-agonist, precision engineered by Cue scientists and designed to unlock the potential of TGF-β biology and restore immune tolerance. We believe this differentiated approach offers broad opportunities to address high unmet needs across autoimmune diseases. We look forward to sharing further progress as we advance our portfolio of therapies aimed at delivering durable, disease-modifying benefits across allergic and autoimmune diseases.”
Business Highlights
CUE-221: Phase 2 CSU Study Results
We announced positive Phase 2 CSU topline results demonstrating highly statistically significant dose responsive clinical impact on the primary endpoint of complete hives resolution (HSS7=0) and statistically significant improvement on the key secondary endpoint of complete response (UAS7=0).
Previously reported durable clinical benefit (HSS7=0) at week 28 (12 weeks after the last dose) in the 4mg/kg dose group persisted in the absence of clinically meaningful drug exposure, was not observed at lower doses, and was significantly greater than XOLAIR® (omalizumab) in a post-hoc analysis, implicating biological effects beyond IgE neutralization alone. These findings are consistent with CUE-221’s dual mechanism of action designed to both neutralize IgE and prevent the synthesis of new IgE.
The study enrolled patients across a broad range of baseline IgE (median of 427 ng/mL [178 IU/m], range up to 7860, ng/mL, with approximately one-third having high IgE ≥ 720 ng/mL (300 IU/mL).
In the study, CUE-221 demonstrated rapid, profound and dose-responsive free IgE suppression. At 4 mg/kg, all patients in the intensive PK subgroup achieved levels below the limit of quantification within hours of dosing with >90% of the overall population achieving these levels at the first post-dose assessment at week 1, including patients with baseline IgE exceeding the XOLAIR® food allergy dosing table. Median free IgE rose at the end of each 4-week dosing interval (26% of baseline at the end of the first dosing interval), with extent of return progressively diminishing at the end of each subsequent dosing interval.
In a prespecified subgroup analysis of patients with high baseline IgE ≥ 300 IU/mL, 78% of patients receiving 4 mg/kg achieved complete hive resolution (HSS7=0) at week 12 versus 0% with placebo (P < 0.005). A subsequent post-hoc analysis also demonstrated a statistically significant higher complete response (UAS7=0) rate of 67% versus 0% with placebo (p < 0.05). Together these data suggest that baseline IgE may predict response in CSU and highlight the clinical potential of CUE-221 in patients with high baseline IgE across disease states, including food allergy.
Collectively, the Phase 1 and Phase 2 CSU studies of CUE-221 demonstrated favorable and well-tolerated safety profiles, up to 10 mg/kg. No neutralizing antibodies have been observed. The phase 2 study identified 4 mg/kg as the dose at which differentiated clinical benefit emerged relative to low
Aug 14, 2026 · 98% conf.
1D
-0.95%
$33.88
Act: -19.18%
5D
+3.52%
$35.40
20D
-13.93%
$29.43
2 cue-ex99_1.htm
Exhibit 99.1
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications
• Completed a $50 million private placement (PIPE) to further fund clinical development and the portfolio with significant potential for value-inflection
• Strengthened the leadership team with the appointments of the Chief Medical Officer and Head of R&D and the Chief Financial Officer
• Operating results reflected higher expenditures related to the licensing and initiation of the CUE-221 development program, driven by one-time non-cash charges and acquisition-related payments
BOSTON, August 14, 2026 – Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.
“I am pleased with our progress this quarter, advancing our pipeline and strengthening our position for long-term growth,” said Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma. “The CUE-221 license agreement augments our portfolio and opportunities, and the higher expenditures this quarter reflect expected one-time non-cash items and payments related to the transaction. Combined with our recent CUE-221 IND submission, financing with high-quality investors, and strategic leadership additions, we believe we are well positioned for the next phase of execution. We look forward to anticipated CUE-221 Phase 2 data by the end of this quarter and remain on track to initiate a CUE-401 Phase 1 study by the end of the year.”
Business, Financial and Leadership Highlights
Milestones
• Recently submitted an IND to the FDA in food allergy applications
• Phase 2 data readout in Chronic Spontaneous Urticaria anticipated by the end of the third quarter of 2026
• Company anticipates submitting an IND to the FDA and initiating a Phase 1 clinical study by year-end 2026
Financial and Corporate
• Completed a private placement for gross proceeds of $50 million primarily to support clinical development, pipeline advancement, and infrastructure growth
Leadership
• Dr. Dominic Borie, Chief Medical Officer and Head of Research and Development, physician-scientist and immunology leader with deep expertise in immunology, joined Cue to help advance key clinical programs in allergic and autoimmune diseases
• Mr. James M. Ahlers, Chief Financial Officer, a veteran biotechnology finance executive, joined Cue to help strengthen the Company’s financial leadership and the infrastructure needed to support execution of its corporate strategy
Second Quarter 2026 Financial Results Second quarter revenue was $7.9 million, compared to $3.0 million in the second quarter of 2025. The increase in 2026 was due to revenue earned from the Boehringer Ingelheim collaboration and license agreement upon achievement of a preclinical milestone triggered in the second quarter of 2026.
Research and development expenses were $49.0 million for the three months ended June 30, 2026, compared to $7.9 million in 2025. The increase primarily consisted of one-time cash payments of approximately $20.0 million, including the upfront payment to Ascendant, and transaction-related costs. Additionally, approximately $20.0 million of expense was recognized as the fair value of warrants issued to Ascendant pursuant to the license agreement, with a corresponding credit to shareholders’ equity resulting in no net impact on stockholders’ equity.
General and administrative expenses were $46.6 million for the three months ended June 30, 2026, compared to $3.7 million in 2025. The increase was primarily attributable to one-time expenses incurred in connection with the Company's strategic transformation, including approximately $23.0 million related to integration with a newly assembled, complementary management team and transaction-related costs, as well as approximately $19.7 million of non-cash stock-based compensation expense recognized during the quarter.
Other income and expense for the three months ended June 30, 2026, primarily comprised a net non-cash loss of $63.1 million related to the license agreement with Ascendant. As a result, a loss on
issuance of liability-classified warrants was recognized, partially offset by a gain on the fair value measurement of warrants issued.
Net loss for the three months ended June 30, 2026 was $153.1 million, compared to $8.5 million in 2025. The increase was primarily due to one-time non-cash losses accounted for in other income, and one-time expenses related to the license agreement.
As of June 30, 2026, the Company had $17.4 million in cash and cash equivalents after incurring one-time cash outflows related to the license agreement. Subsequent to June 30, 2026, the Company comple
Mar 16, 2026 · 100% conf.
1D
-13.54%
$0.27
Act: -12.84%
5D
-19.74%
$0.25
20D
-24.99%
$0.23
8-K
0001645460false00016454602026-03-162026-03-16
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2026
Cue Biopharma, Inc. (Exact name of registrant as specified in its charter)
Delaware
001-38327
47-3324577
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
40 Guest Street Boston, Massachusetts
02135 (Zip Code)
(Address of principal executive offices)
(617) 949-2680 (Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
CUE
Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.
Results of Operations and Financial Condition.
On March 16, 2026, Cue Biopharma, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits:
Exhibit No.
Description
99.1
Press Release dated March 16, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cue Biopharma, Inc.
Date: March 16, 2026
By:
/s/ Usman Azam
Name: Usman Azam
Title: President and Chief Executive Officer
This page provides Cue Biopharma Inc. (CUE) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on CUE's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.